Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/30/2024 | $20.00 | Buy | H.C. Wainwright |
| 8/13/2024 | $21.00 | Buy | Jefferies |
| 8/13/2024 | $23.00 | Overweight | Cantor Fitzgerald |
| 8/13/2024 | Buy | TD Cowen | |
| 8/13/2024 | $18.00 | Outperform | Wedbush |
| 8/13/2024 | $23.00 | Buy | Needham |
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune indications expected H1 2025 Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00
Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00
Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00
SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)